Vol. 5 No. 2 (2025): February
Reimbursement Reviews

Baricitinib (Olumiant)

decorative image of the issue cover

Published February 7, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses baricitinib (Olumiant), 2 mg and 4 mg oral tablets.
  • Indication: Baricitinib is indicated for the treatment of adult patients with severe alopecia areata.